Publication | Closed Access

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Hematological MalignancyLymphoid NeoplasiaOncologyChronic Lymphocytic LeukaemiaImmunologyHematologyClinical TrialsObinutuzumab Versus ChlorambucilFirst-line TreatmentPharmacotherapyImmunotherapyMedicineHealth Sciences